Stoke Therapeutics (STOK) chief patient officer exercises 10,000 RSUs into shares

Rhea-AI Filing Summary

Stoke Therapeutics Chief Patient Officer Jason Hoitt exercised 10,000 restricted stock units into 10,000 shares of common stock. This was a derivative exercise (code M), not an open-market purchase or sale. Following the transaction, he directly owned 13,988 shares of common stock and 30,000 RSUs.

Each RSU converts into one share of common stock upon settlement. The RSU award vests in four equal annual installments beginning on March 15, 2026, subject to his continued service. The reported ownership total also reflects 2,186 shares previously acquired through the company’s employee stock purchase plan.

Insider Trade Summary

10,000 shares exercised/converted

Mixed 2 txns

Insider Hoitt Jason

Role Chief Patient Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	10,000	$0.00	--
Exercise	Common Stock	10,000	$0.00	--

Holdings After Transaction: Restricted Stock Units — 30,000 shares (Direct); Common Stock — 13,988 shares (Direct)

Footnotes (1)

1. The reported total includes an aggregate 2,186 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoitt Jason

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Patient Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		10,000	A	$0	13,988(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/15/2026		M			10,000	(3)	03/15/2029	Common Stock	10,000	$0	30,000	D

Explanation of Responses:

1. The reported total includes an aggregate 2,186 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).

2. Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

3. The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Stoke Therapeutics (STOK) report for Jason Hoitt?

Stoke Therapeutics reported that Chief Patient Officer Jason Hoitt exercised 10,000 restricted stock units into 10,000 shares of common stock. This derivative exercise was coded “M” and did not involve an open-market buy or sell transaction.

How many Stoke Therapeutics (STOK) shares does Jason Hoitt hold after this Form 4?

After the reported transactions, Jason Hoitt directly owns 13,988 shares of Stoke Therapeutics common stock. He also holds 30,000 restricted stock units, each representing the right to receive one share of common stock upon settlement under the company’s equity plan.

What type of securities did Jason Hoitt exercise in the Stoke Therapeutics (STOK) filing?

Jason Hoitt exercised 10,000 restricted stock units, which are derivative equity awards that convert into common shares. Each RSU represents a contingent right to receive one share of Stoke Therapeutics common stock when the unit vests and is settled.

How do Jason Hoitt’s restricted stock units in Stoke Therapeutics (STOK) vest?

Jason Hoitt’s RSU award vests in four equal annual installments, with one quarter of the total vesting each year beginning March 15, 2026. Continued service with Stoke Therapeutics is required through each vesting date for the corresponding RSUs to vest.

Were any Stoke Therapeutics (STOK) shares bought or sold on the open market in this Form 4?

No open-market purchases or sales were reported. The Form 4 reflects a derivative exercise of 10,000 restricted stock units into 10,000 common shares, coded “M,” which is distinct from a standard buy or sell on the public market.

What does the footnote about the Stoke Therapeutics (STOK) Employee Stock Purchase Plan indicate?

The footnote explains that Hoitt’s reported total common stock holdings include 2,186 shares acquired through the Employee Stock Purchase Plan. These shares were obtained in one or more transactions exempt under SEC Rules 16b-3(c) and 16b-3(d).